Literature DB >> 31425225

Initial Postoperative Hemoglobin Values and Clinical Outcomes in Transfused Patients Undergoing Noncardiac Surgery.

Nicholas D Will1, Daryl J Kor2, Ryan D Frank3, Melissa A Passe4, Timothy J Weister4, Martin D Zielinski5, Matthew A Warner2.   

Abstract

BACKGROUND: Intraoperative red blood cell (RBC) transfusion is common, yet transfusion strategies remain controversial as pretransfusion hemoglobin triggers are difficult to utilize during acute bleeding. Alternatively, postoperative hemoglobin values may provide useful information regarding transfusion practices, though optimal targets remain undefined.
METHODS: This is a single-center observational cohort study of adults receiving allogeneic RBCs during noncardiac surgery from 2010 through 2014. Multivariable regression analyses adjusting for patient illness, laboratory derangements, and surgical features were used to assess relationships between initial postoperative hemoglobin values and a primary outcome of hospital-free days.
RESULTS: A total of 8060 patients were included. Those with initial postoperative hemoglobin <7.5 or ≥11.5 g/dL had decreased hospital-free days [mean (95% confidence interval [CI]), -1.45 (-2.50 to -0.41) and -0.83 (-1.42 to -0.24), respectively] compared to a reference range of 9.5-10.4 g/dL (overall P value .003). For those with hemoglobin <7.5 g/dL, the odds (95% CI) for secondary outcomes included acute kidney injury (AKI) 1.43 (1.03-1.99), mortality 2.10 (1.18-3.74), and cerebral ischemia 3.12 (1.08-9.01). The odds for postoperative mechanical ventilation with hemoglobin ≥11.5 g/dL were 1.33 (1.07-1.65). Secondary outcome associations were not significant after multiple comparisons adjustment (Bonferroni P < .0056).
CONCLUSIONS: In transfused patients, postoperative hemoglobin values between 7.5 and 11.5 g/dL were associated with superior outcomes compared to more extreme values. This range may represent a target for intraoperative transfusions, particularly during active bleeding when pretransfusion hemoglobin thresholds may be impractical or inaccurate. Given similar outcomes within this range, targeting hemoglobin at the lower aspect may be preferable, though prospective validation is warranted.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31425225     DOI: 10.1213/ANE.0000000000004287

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Intraoperative Transfusion Targets: Avoiding the Extremes.

Authors:  Nadia B Hensley; Steven M Frank; Micah T Prochaska
Journal:  Anesth Analg       Date:  2019-09       Impact factor: 5.108

2.  Threshold heterogeneity of perioperative hemoglobin drop for acute kidney injury after noncardiac surgery: a propensity score weighting analysis.

Authors:  Yan Zhou; Si Liu
Journal:  BMC Nephrol       Date:  2022-06-11       Impact factor: 2.585

3.  Hospital discharge hemoglobin values and posthospitalization clinical outcomes in transfused patients undergoing noncardiac surgery.

Authors:  Mitchell J Kerfeld; Daryl J Kor; Ryan D Frank; Andrew C Hanson; Melissa A Passe; Matthew A Warner
Journal:  Transfusion       Date:  2020-08-13       Impact factor: 3.157

4.  Perioperative Transfusion Associated With Increased Morbidity and Mortality in Geriatric Patients Undergoing Hip Fracture Surgery.

Authors:  Piyush Gupta; Kevin K Kang; Jordan B Pasternack; Elliot Klein; Dennis E Feierman
Journal:  Geriatr Orthop Surg Rehabil       Date:  2021-05-16

5.  Sex-Specific Associations Between Preoperative Anemia and Postoperative Clinical Outcomes in Patients Undergoing Cardiac Surgery.

Authors:  Juan G Ripoll; Mark M Smith; Andrew C Hanson; Phillip J Schulte; Erica R Portner; Daryl J Kor; Matthew A Warner
Journal:  Anesth Analg       Date:  2021-04-01       Impact factor: 6.627

6.  The Prevalence and Clinical Significance of Preoperative Thrombocytopenia in Adults Undergoing Elective Surgery: An Observational Cohort Study.

Authors:  Luke J Matzek; Andrew C Hanson; Phillip J Schulte; Kimberly D Evans; Daryl J Kor; Matthew A Warner
Journal:  Anesth Analg       Date:  2021-03-01       Impact factor: 6.627

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.